In prostate cancer, TOP2A expression has been demonstrated to be related to epigenetic modulation via the enhancer of zeste homolog2 (EZH2), while its abnormal expression is associated with the cancer phenotype [3,6]. This evidence concerns the gene TOP2A and cancer.